All News

Using machine learning, they find patterns in electronic health record data to help ascertain which individuals likely have the condition.

How would you handle these patients' questions?

Investigators establish 2 predictive models, which had excellent performance, and included 90 children.

Treatment with nirogacestat resulted in a 71% reduction in the risk of disease progression among adults with progressing desmoid tumors.

This month's generic product news features clarithromycin, sevelamer hydrochloride, and metronidazole.

Consequences for untreated STEMI patients following the COVID-19 pandemic could include increased mortality, heart failure, and morbidities.

Pharmacists are an important touch point for PQA, and they're starting small and thinking big.

Immunocompromised patients are particularly at risk of developing persistent and severe anemia caused by parvovirus infections.

Any antibiotic use was associated with higher rates of IBD, and the risk went up substantially with each course.

Linaclotide (Linzess) is indicated in adults for treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

PQA is also committed to national goals related to HIV and reducing HIV ending the epidemic.

CalmAid helps reduce stress and tension.

The approval is supported by data from a global phase 3 trial assessing the use of the drug for individuals with previously untreated IDH1-mutated acute myeloid leukemia.

Emflaza is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

With the new approval, manufacturers believe 7000 new rings will be able to enter the supply chain and will be available to customers in the second and third quarters of 2022.

PQA is focused on actually testing the feasibility and implementation of some of these measures as concepts.

Dong Xu, PhD, MS, curators' distinguished professor at the University of Missouri College of Engineering, discusses how the use of artificial intelligence may help develop new drug therapies targeting multiple disease states.

Karen Fancher, PharmD, BCOP, a member of the Patient Advisory Panel at the Hematology/Oncology Pharmacy Association (HOPA), explains how her experience as a patient with cancer and an oncology pharmacy specialist informs her work on HOPA’s Patient Advisory Panel.

Pet peeves are brought to you by The Sassy Pharmacist.

The study results support a hypothesis for a differentiated mechanism from risankizumab, the company says.

This month's Rx product news features empagliflozin, mitapivat, and RSVpreF.

Sacubitril/valsartan (Entresto)reduces the risk of hospitalization and death related to cardiovascular complications in patients with heart failure.

Byron Yoshino, PharmD, CEO of Pharmacare Hawaii, discusses the future of the home infusion space within the United States in the coming years.

Investigators found that 51% of participants achieved sustained unresponsiveness to peanut after 18 months of treatment.

Dr. Jacinda Abdul-Mutakabbir is dedicated to magnifying and rectifying health inequities in minoritized communities, which is why health equity is so important to her in healthcare.

Without sufficient vitamin D exposure, bones can become thin, brittle, or misshapen; however, excessive amounts of vitamin D are toxic.

This product helps control blood pressure.

Symtuza, a 4-drug combination of darunavir (DRV), a HIV-1 protease inhibitor; cobicistat (COBI), a CYP3A inhibitor; and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, is indicated as a complete regimen for the treatment of HIV-1 infection in patients who weigh at least 40 kg.